TickerTalks
Browse all tickers →
TickerTalks›$MRK
MRMRK

Merck & Co., Inc.

$MRK·$360B·Drug Manufacturers - General·Healthcare
$145.97+0.5%YTD+34.5%1Y+73.9%
Price updated 6h ago·X counts updated 5d ago
MRMRK
$MRKMerck & Co., Inc.
$145.97+0.53%512 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $MRK on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

512X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $MRK's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 62% of tracked names.

Bearish sentimentAI analysisGenerated by AI from underlying data13 posts analyzed · as of 2026-10-02

Sentiment is bearish on an ADC-pipeline failure — Merck voluntarily withdrew the ifinatamab-deruxtecan (I-DXd) BLA for extensive-stage SCLC on Friday evening, and X is counting that two of the three Daiichi ADCs are now dead (HER3-DXd and I-DXd). B7H3ADC's Phase 3 reportedly saw "several cases of G5 pneumonitis." The bulls lean on legacy politics (Capitol Hill buys, iH&S pattern), but the news flow is the story.

Read what X is saying about $MRK

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $MRK — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersCooling offAI verdict · as of 2026-10-03

Catching its breath after a run — could pick back up or fade from here.

A pharma heavyweight whose ADC bets just got cut from three to one — Keytruda still prints, the pipeline just thinned.

Merck is a US pharma giant whose single biggest asset is still Keytruda, but whose future earnings depend on the next-generation pipeline. Friday's voluntary BLA withdrawal of ifinatamab-deruxtecan for extensive-stage SCLC is a real pipeline setback — it leaves two of the three Daiichi-partnered ADCs dead and raises questions about B7H3ADC's Phase 3 safety signal.

  • The P&L is still carrying the business: last quarter revenue grew 4.3% YoY to $16.3B, but a -11.6% operating margin and a -$1.72 EPS print reflect large non-cash charges — the trailing EPS surprises of +52% and +13% show the underlying earnings power is still intact.
  • The pipeline risk is now specific and dated: the ADC program has one shot left, and B7H3's Phase 3 pneumonitis signal (multiple G5 pneumonitis events reported in sentiment) is exactly the safety profile the FDA won't let through at scale.

At 83% of its 52-week range going into Oct 29 earnings, the stock is pricing less-than-the-pipeline-is-telling-you. A clean Keytruda number plus any constructive update on tulisokibart or incoming pipeline is what stabilizes; another ADC safety signal is where the cooling trajectory turns to breaking-down.

Agrees with X sentimentThe bearish ADC-pipeline read is grounded on specific scientific signals — this isn't hand-waving, it's two drug withdrawals and a Phase 3 safety concern. The legacy-politics bull hooks are weak counter-arguments; the pipeline matters more than Capitol Hill buys here.

What to watch: Oct 29 Q3 earnings and any further B7H3ADC safety disclosures — Keytruda growth, tulisokibart commentary, and any Daiichi-partnership updates. A clean Keytruda print plus constructive tulisokibart data stabilizes; another ADC setback is the invalidation.

On the calendar: 2026-10-29 — Q3 earnings

event ahead 30dpipeline setback

Read the AI verdict on $MRK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes Keytruda cancer immunotherapy, Gardasil HPV vaccine, and animal health products with a strong oncology pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $MRK.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $MRK

Neutral — Makes Keytruda cancer immunotherapy, Gardasil HPV vaccine, and animal health products with a strong oncology pipeline.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
33.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
27.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
17.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
75.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.13$-0.27+51.9%
Q1 2026Apr 30, 2026$-1.28$-1.47+12.9%
Q4 2025Feb 3, 2026$2.04$2.01+1.5%
Q3 2025Oct 30, 2025$2.58$2.36+9.3%
Next earningsThu, Oct 29·consensus EPS $2.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$16.3B+4.3%81.9%-11.6%$-1.72$2.9B
Q4 FY25$16.3B+4.5%70.5%37.7%$1.20$1.8B
Q3 FY25$17.2B+3.2%75.6%43.4%$2.32$6.8B
Q2 FY25$15.8B-1.9%75.7%40.2%$1.76$2.5B

Forward consensus

5-year forecast · up to 20 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$67.1B$66.8B – $67.2B$2.70$2.52 – $2.7917
FY27$69.9B$69.0B – $71.9B$9.36$8.56 – $9.9618
FY28$74.0B$70.9B – $79.7B$10.31$8.36 – $12.3120
FY29$75.1B$73.7B – $77.2B$10.17$9.92 – $10.5410
FY30$75.8B$74.4B – $77.9B$10.16$9.91 – $10.5210

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.85%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 2.5B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.225-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 13Chirfi GuindoEVP, Access, Policy & Comms10.0K sh$1.4MSellAug 12Jennifer ZacharyEVP, General Counsel80.3K sh$10.7MSellAug 12Richard R. DelucaEVP&Pres, Merck Animal Heallth11.7K sh$1.5MSellAug 11Richard R. DelucaEVP&Pres, Merck Animal Heallth12.8K sh$1.7MSellAug 10Richard R. DelucaEVP&Pres, Merck Animal Heallth20.8K sh$2.7MSellAug 6Richard R. DelucaEVP&Pres, Merck Animal Heallth6.0K sh$789KSellAug 6Chirfi GuindoEVP, Access, Policy & Comms15.0K sh$2.0MSellAug 5David R. MaraldoEVP & Pres. MMD2.7K sh$346KSellAug 5Williams David MichaelEVP,Chief Info&Digital Officer34.7K sh$4.5M
+ 45 other (30 awards · 9 exempts · 6 inkinds) in window

See when $MRK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeOct 138-K — Item 5.02: Officer or director change
3New insider — initial holdingsSep 13
AI summary

Merck & Co., Inc. (MRK) filed Form 3 reporting Gaurav K. Gupta as a new officer as of September 1, 2026, in the role of Executive Vice President and Chief Information and Digital Officer (EVP, CIDO). Gupta directly holds 750 shares of Merck common stock with no derivative securities reported. This is a routine officer-onboarding disclosure; the appointment of a new EVP CIDO is administratively significant but carries no material financial impact on its own.

8-KShareholder voteMay 288-K — Item 5.07: Shareholder vote
AI summary

Merck & Co., Inc. held its Annual Meeting of Shareholders on May 26, 2026, at which shareholders voted on director elections, executive compensation (say-on-pay), and other proposals as described in the proxy statement. Final voting results for each nominee and proposal are provided in the 8-K. This is a routine annual meeting governance disclosure with no material corporate actions taken.

424B5Prospectus supplement (offering)May 20424B5
AI summary

Merck & Co., Inc. (MRK) priced a $6 billion multi-tranche senior notes offering on May 20, 2026, comprising: $500M Floating Rate Notes due 2028, $1B 4.300% Notes due 2028, $500M 4.650% Notes due 2031, $1B 4.950% Notes due 2033, $1.5B 5.200% Notes due 2036, $500M 5.750% Notes due 2046, and $1B 5.850% Notes due 2056. This is a large investment-grade debt capital markets transaction for Merck; proceeds are likely earmarked for general corporate purposes, which may include funding the company's acquisition strategy or refinancing maturing debt.

424B5Prospectus supplement (offering)May 18424B5
AI summary

Merck and Co., Inc. (MRK) filed a preliminary 424B5 prospectus supplement on May 18, 2026 under Registration No. 333-278066 for a multi-tranche debt offering comprising Floating Rate Notes and multiple fixed-rate note series at various maturities. All specific dollar amounts and interest rates are left blank in this pre-pricing document. This is a debt capital markets transaction (not equity dilution) with proceeds intended for general corporate purposes consistent with Merck's ongoing capital needs.

3/ANew insider — initial holdingsMay 53/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for MRK on 2026-05-05, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2026 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsMay 43
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for MRK on 2026-05-04, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2026 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

+ 15 other (3 11-Ks · 2 10-Qs · 2 13Fs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Merck Stock: Watch This Price, Prepare To Profit From This Tradeinvestors.com·14h agoThe Stocks That Will Get Investors Home Safe When Tech Cracks247wallst.com·17h agoThe Big 3: MRK, GILD, XOMyoutube.com·2d agoAMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow247wallst.com·2d agoHere is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stockzacks.com·2d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OGN$LLY$NVO$PFE$JNJ$ABBV$BMY$AMGN
Voices on X · top 10 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport